All publications

Export 11 results:
[ Author(Asc)] Title Type Year
Filters: First Letter Of Last Name is P  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
P
Prosperi M.C, Mackie N, Di Giambenedetto S., Zazzi M, Camacho R., Fanti I., Torti C., Sonnerborg A., Kaiser R., Codoner F.M et al..  2011.  Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. J Antimicrob Chemother. 66:1886-96.
Price H., Asboe D, Pozniak A, Gazzard B, Fearnhill E, Pillay D, Dunn DT.  2010.  Positive and negative drug selection pressures on the N348I connection domain mutation: new insights from in vivo data. Antivir Ther. 15:203-11.
Price H., Dunn DT, Asboe D, Pozniak A, Gazzard B, Pillay D, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.  2009.  Positive and negative drug selection pressures on the N348I connection domain mutation; new insights from in vivo data. 18th International HIV Drug Resistance Workshop, June 2009.
Pond S.LKosakov, Posada D., Stawiski E., Chappey C., Poon A.F, Hughes GJ, Fearnhill E, Gravenor M.B, Leigh Brown A, Frost S.D.  2009.  An evolutionary model-based algorithm for accurate phylogenetic breakpoint mapping and subtype prediction in HIV-1. PLoS Comput Biol. 5:e1000581.
Pillay D, Green H, UK HIV Drug Resistance Database.  2003.  The UK HIV Drug Resistance Database: development and use for national surveillance. 12th International HIV Drug Resistance Workshop, 10-14 June 2003.
Pillay D, Dunn DT.  2009.  The biology, epidemiology and clinical implications of transmitted HIV drug resistant viruses. 16th Conference on Retroviruses and Opportunistic Infections, February 2009.
Pillay D, Green H, Gazzard B, Pozniak A, Matthias R, Johnson M, Churchill D, Fisher M, Hill T, Geretti AM et al..  2004.  Estimating resistance in drug experienced patients in the UK. 13th International Drug Resistance Workshop, 8-12 June 2004.
Pillay D, Green H, Matthias R, Dunn DT, Phillips AN, Sabin CA, Evans B..  2005.  Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom. J Infect Dis. 192:967-73.
Phillips AN, Dunn DT, Sabin CA, Pozniak A, Matthias R, Geretti AM, Clark J, Churchill D, Williams I, Hill T et al..  2004.  Risk of development of drug resistance in patients starting antiretroviral therapy with three or more drugs in routine clinical practice. 13th International Drug Resistance Workshop, 8-12 June 2004.
Phillips AN, Dunn DT, Sabin CA, Pozniak A, Matthias R, Geretti AM, Clark J, Churchill D, Williams I, Hill T et al..  2004.  Long term risk of development of drug resistance after starting antiretroviral therapy in routine clinical practice. 7th International Congress on Drug Therapy in HIV Infection, 14-17 November 2004.
Phillips AN, Dunn DT, Sabin CA, Pozniak A, Matthias R, Geretti AM, Clark J, Churchill D, Williams I, Hill T et al..  2005.  Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS. 19:487-94.